Who Made Wegovy and Why That Matters for UK Patients

Why Novo Nordisk spent years on semaglutide before it became Wegovy

Novo Nordisk did not arrive at Wegovy overnight. The company spent the better part of two decades refining the semaglutide molecule, first as a treatment for type 2 diabetes, that formulation reached patients as Ozempic, licensed for blood-sugar control, not weight loss. The weight-management application required a different dose, a separate clinical programme and its own regulatory approval. The STEP trials, including the landmark STEP 1 study published in the New England Journal of Medicine, tested semaglutide 2.4mg against placebo over 68 weeks and recorded an average body-weight reduction of around 15%.

That body of evidence is what Novo Nordisk submitted to regulators globally. In the UK, it is the MHRA that examines the data, sets the conditions of use and grants (or withholds) a marketing authorisation. The authorisation holder for Wegovy in the UK is Novo Nordisk Ltd. That means the company is legally responsible for the quality of every pen that reaches a patient, for pharmacovigilance, and for reporting any new safety signals to the MHRA.

A question our prescribers hear most weeks is whether Wegovy bought through unofficial channels is the same medicine. It isn't necessarily. The manufacturer's quality controls only apply to product that travels through the licensed UK supply chain. If you want to learn more about how Wegovy is made at a manufacturing level, the process of producing biological medicines like semaglutide is carefully controlled and not easily replicated, which is precisely why counterfeit versions exist and pose a genuine risk.

What it means that Ozempic and Wegovy share the same active ingredient but different licences

Semaglutide is semaglutide. But the medicine you receive, the dose it contains and the condition it is licensed to treat are determined by the product's marketing authorisation, not by the molecule alone. Ozempic is semaglutide licensed for type 2 diabetes. If you are curious about who made semaglutide and how it came to exist in two distinct licensed forms, the history behind the molecule helps explain why Novo Nordisk makes both products yet treats them as separate medicines. They are different products with different approved uses, even though Novo Nordisk makes both.

This distinction matters practically. A prescriber who issues Wegovy for weight management is working within the licensed indication. A prescriber issuing Ozempic for the same purpose is prescribing off-label, a different clinical and regulatory context. The NHS medicines information for semaglutide covers both products and is worth reading if you want to understand the full picture of what Novo Nordisk's semaglutide medicines do and how they differ.

For people researching weight management options, the practical upshot is straightforward: the relevant Novo Nordisk product for weight loss is Wegovy, and it requires a valid UK prescription following clinical assessment. You can read more about semaglutide as a weight-loss medicine and how the two licensed formulations sit alongside each other.

The manufacturer's track record and what changed in 2026

Novo Nordisk's involvement in semaglutide did not stop at the injection pen. In January 2026, the MHRA approved a higher 7.2mg maintenance dose for Wegovy, with a dedicated single-dose pen following in April 2026, designed with an auto-dosing mechanism and a built-in covered needle. Then, on 11 June 2026, Novo Nordisk reached another milestone: the MHRA approved Wegovy tablets as the first oral GLP-1 medicine licensed in the UK for weight management, with the UK becoming the first country in Europe to approve it. The oral version uses a co-formulation with an absorption enhancer called SNAC, allowing semaglutide to be absorbed through the stomach lining rather than injected.

Each of these changes required new regulatory submissions, new clinical evidence and fresh MHRA scrutiny. That process is what distinguishes a manufacturer with a legitimate authorisation from sellers operating outside it. If you are weighing up which Wegovy formulation might suit you, that decision rests with a prescriber rather than with the manufacturer's marketing; you can explore Wegovy as a treatment option in more detail, and the weight-loss treatment overview covers how injectable and oral options compare at a practical level. Costs vary by dose and provider, and an honest breakdown of what private treatment involves is worth reading on the Wegovy access and cost context page before you make any decisions.

Why the manufacturer question connects to safety when buying online

Understanding that Novo Nordisk holds the UK marketing authorisation for Wegovy is useful beyond satisfying curiosity, and if you want a fuller picture of who Wegovy is made by and what that accountability means in practice, that context helps explain why supply chain integrity matters so much. The MHRA has issued repeated warnings about fake weight-loss pens circulating online and via social media, versions that bear no connection to the manufacturer's quality standards and have, in some cases, been found to contain different substances entirely.

The safest route to any prescription medicine in the UK is through a pharmacy registered with the General Pharmaceutical Council, which you can verify using the GPhC pharmacy register. Sellers offering Wegovy without a prescription, or at prices far below the typical UK private market, are a red flag regardless of what branding they display. The manufacturer's name on packaging is not a guarantee of authenticity if the product has not reached you through the licensed supply chain.

At nume, our prescribers review every consultation personally before any medicine is dispensed, our GPhC-registered pharmacy sources through the authorised UK supply chain. If you'd like to check whether you're clinically suitable for Wegovy, check your eligibility with a free consultation.